A1C for Screening and Diagnosis of Type 2 Diabetes in Routine Clinical Practice

被引:67
作者
Lu, Zhong X. [1 ,2 ]
Walker, Karen Z. [3 ,4 ]
O'Dea, Kerin [5 ]
Sikaris, Ken A. [1 ]
Shaw, Jonathan E. [6 ]
机构
[1] Melbourne Pathol Serv, Melbourne, Vic, Australia
[2] Monash Univ, Monash Med Ctr, Dept Med, Melbourne, Vic 3004, Australia
[3] Monash Univ, Dept Nutr & Dietet, Melbourne, Vic 3004, Australia
[4] Baker IDI Heart & Diabet Inst, Preventat Hlth Unit, Melbourne, Vic, Australia
[5] Univ S Australia, Sansom Inst Hlth Res, Adelaide, SA 5001, Australia
[6] Baker IDI Heart & Diabet Inst, Clin Diabet & Epidemiol Unit, Melbourne, Vic, Australia
基金
英国医学研究理事会;
关键词
IMPAIRED GLUCOSE-TOLERANCE;
D O I
10.2337/dc09-1763
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To evaluate A1C for screening and diagnosis of undiagnosed type 2 diabetes defined by oral glucose tolerance testing in clinical and general populations. RESEARCH DESIGN AND METHODS - A1C cut offs (<= 5.5% to rule out diabetes; >= 7.0% to rule in diabetes) were derived from a clinical group (Melbourne Pathology [MP] group: n = 2,494; undiagnosed diabetes 34.6%) and then evaluated in a population-based sample (AusDiab group: n = 6,015; undiagnosed diabetes 4.6%). RESULTS - For diabetes in the MP and AusDiab groups, A1C at 5.5% gave sensitivities of 98.7 and 83.5%, while A1C at 7.0% gave specificities of 98.2 and 100%, respectively. Many (61.9-69.3%) with impaired A1C (5.6-6.9%) in both populations had abnormal glucose status. CONCLUSIONS - A1C <= 5.5% and 7.0% predicts absence or presence of type 2 diabetes, respectively, while at A1C 6.5-6.9% diabetes is highly probable in clinical and population settings. A high proportion of people with impaired A1C have abnormal glucose status requiring follow-up.
引用
收藏
页码:817 / 819
页数:3
相关论文
共 15 条
[1]   Standards of medical care in diabetes 2008 [J].
不详 .
DIABETES CARE, 2008, 31 :S12-S54
[2]  
Balion CM, 2007, CLIN CHEM LAB MED, V45, P1180, DOI 10.1515/CCLM.2007.250
[3]   HbA1c as a screening tool for detection of Type 2 diabetes:: a systematic review [J].
Bennett, C. M. ;
Guo, M. ;
Dharmage, S. C. .
DIABETIC MEDICINE, 2007, 24 (04) :333-343
[4]   Utility of AIC for diabetes screening in the 1999-2004 NHANES population [J].
Buell, Catherine ;
Kermah, Duclie ;
Davidson, Mayer B. .
DIABETES CARE, 2007, 30 (09) :2233-2235
[5]   The rising prevalence of diabetes and impaired glucose tolerance - The Australian diabetes, obesity and lifestyle study [J].
Dunstan, DW ;
Zimmet, PZ ;
Welborn, TA ;
de Courten, MP ;
Cameron, AJ ;
Sicree, RA ;
Dwyer, T ;
Colagiuri, S ;
Jolley, D ;
Knuiman, M ;
Atkins, R ;
Shaw, JE .
DIABETES CARE, 2002, 25 (05) :829-834
[6]  
Fonseca VA, 2009, DIABETES CARE, V32, P1, DOI [10.2337/dc09-9033, 10.2337/dc09-S301]
[7]   Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis [J].
Gillies, Clare L. ;
Abrams, Keith R. ;
Lambert, Paul C. ;
Cooper, Nicola J. ;
Sutton, Alex J. ;
Hsu, Ron T. ;
Khunti, Kamlesh .
BMJ-BRITISH MEDICAL JOURNAL, 2007, 334 (7588) :299-302B
[8]   Value of risk stratification to increase the predictive validity of HbA1c in screening for undiagnosed diabetes in the US population [J].
Ginde, Adit A. ;
Cagliero, Enrico ;
Nathan, David M. ;
Camargo, Carlos A., Jr. .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2008, 23 (09) :1346-1353
[9]   Cost-effectiveness analysis of different screening procedures for type 2 diabetes -: The KORA Survey 2000 [J].
Icks, A ;
Haastert, B ;
Gandjour, A ;
John, J ;
Löwel, H ;
Holle, R ;
Giani, G ;
Rathmann, W .
DIABETES CARE, 2004, 27 (09) :2120-2128
[10]   Glucose Indices, Health Behaviors, and Incidence of Diabetes in Australia The Australian Diabetes, Obesity and Lifestyle Study [J].
Magliano, Dianna J. ;
Barr, Elizabeth L. M. ;
Zimmet, Paul Z. ;
Cameron, Adrian J. ;
Dunstan, David W. ;
Colagiuri, Stephen ;
Jolley, Damien ;
Owen, Neville ;
Phillis, Patrick ;
Tapp, Robyn J. ;
Welborn, Tim A. ;
Shaw, Jonathan E. .
DIABETES CARE, 2008, 31 (02) :267-272